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Abstract 
Campylobacter jejuni is a gram negative bacterium which is one of the leading causes of bacterial related acute 
entritis in the developing world. C. jejuni is also linked to auto- immune diseases such as Miller- Fisher syndrome 
and Guillain- Barre Syndrome. C. jejuni is highly effective in colonizing chicken intestinal mucosa without 
causing any clinical symptoms and the consumption of poultry meat is the major source of transmission of bacteria 
to humans. One of the approaches to reduce Campylobacter related illnesses is to reduce the burden of 
Campylobacters in chickens. This can be achieved by vaccinating chickens against Campylobacter; however, 
various approaches to develop a vaccine against Campylobacter have yet to yield a commercial vaccine. One 
approach to develop a new class of vaccines against Campylobacter or other pathogens is to use an attenuated 
Salmonella autotrophic mutant as a vector to deliver antigens of Campylobacter origin to chickens. Our results 
indicate that Salmonella mutants can be effectively used as vector to deliver antigens of Campylobacter origin for 
vaccine purposes. However, before this method can be commercialized several parameters including the choice of 
suitable antigen or antigens needs to be evaluated.  
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1. Introduction 
Campylobacter jejuni is a gram negative bacterium which colonises chicken without causing any 
clinical manifestations, and it is also one of the major causes of gastroenteritis in developed countries. 
Antibodies generated against Campylobacter can bind to some self- antigens causing autoimmune 
diseases such as Gullian-Barre syndrome and Miller Fisher syndrome in humans [1]. The most 
intriguing aspect of Campylobacter pathogenesis is their capability to evade chicken immune 
responses, although they heavily colonise (up to 109 bacteria/gm) chickens intestinal mucosa [2]. Post 
harvesting measures such as chilling and chlorine washing of poultry meat have been somewhat 
effective in reducing the transmission of C. jejuni to humans but these measures are not sufficient to 
eliminate Campylobacter related gastroenteritis. Also such treatments are costly and degrade the 
quality of meat [3]. Vaccinating chickens against Campylobacter spp. is one effective way to reduce 
the bacterial burden on chickens; this will not only reduce chicken to human transmission but also 
eliminate costly post harvest treatments [4]. Although several methods have been tested to design 
effective vaccination against selected Campylobacter spp., so far these methods have not materialised 
in developing a viable vaccine against Campylobacter [3].  Recently several studies have successfully 
tested the use of Salmonella enterica enterica, serovar Typhimurium (S. Typhimurium) mutants as 
delivery vector to deliver antigens from other pathogens for vaccine purpose [5, 6]. These antigens can 
be delivered either from a plasmid location or from the chromosomal location, expressed under the 
influence of various inducible promoters [7]. Similarly in our lab we have successfully tested the use of 
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Salmonella Typhimurium mutant-1 (STM-1) to deliver various heterologous antigens for vaccine 
purposes [7, 8]. STM-1 is an aroA mutant i.e. the aroA gene has been deleted; this leads to a non-
reverting aromatic biosynthesis defects.  This renders the STM-1 non-virulent in respect to invasive 
infection, because aromatic metabolites such as paraminobenzoate (for synthesising folate), 
dihydroxybenzoate (for synthesising enterochelin) and the aromatic amino acids tyrosine are not 
available in host tissues [9] and so are not available to the STM-1 to support active replication. In this 
study we have demonstrated that STM-1 can successfully be used as vector to deliver Campylobacter 
related antigens for vaccines in chickens.  
2. Choice of antigens and design of constructs 
One of the major obstacles in developing vaccination against Campylobacter spp. is to identify suitable 
antigens. There are several proteins which play critical roles in Campylobacter pathogenesis [10]; 
however, the exact role of these proteins in vivo is not well studied, particularly with respect to 
facilitating chicken colonisation. As a strategy to test STM-1 for antigen delivery four antigens were 
selected [11, 12] and were cloned in the PMW2 plasmid (a medium copy number plasmid) and similar 
constructs were inserted into the STM-1 chromosome at the aroA site. Protein expression was analysed 
in vitro by western blotting. After validating the design of the constructs and protein expression, animal 
experiments were undertaken to analyse the efficacy of Salmonella Typhimurium mutant STM-1 to 
deliver these antigens in vivo. 
3. Animal Trials 
In this experiment groups of 4 Chickens (1 week old) were vaccinated with 107 cfu (colony forming 
units) of STM-1 expressing Campylobacter antigens either from the plasmid or chromosomal location. 
The vaccine was administered orally twice at an interval of two weeks. Table 1 shows the experimental 
design. One week after the second vaccination blood samples were collected to analyse humoral 
immune responses against the delivered antigens. On week four (two weeks after the second 
vaccination) all the groups were challenged orally with 109 cfu C. jejuni strain 81116. 
 
Table1. Experimental design of the vaccination trial.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group Vaccine Number 
1 PBS control 4 
2 STM-1 4 
3 STM-1/PMW2 4 
4 cjaA/Chromosome 4 
5 cjaA/PMW2 4 
6 cadF/chromosome 4 
7 cadF/PMW2 4 
8 ciaB/chromosome 4 
9 ciaB/PMW2 4 
10 cj1496/chromosome 4 
11 cj1496/PMW2 4 
12 Combined/chromosome 4 
13 Combined/PMW2 4 
 Total  52 
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All chickens were sacrificed two weeks post challenge and caecal contents from each chicken collected 
in sterile tubes. Each gram of caecal content was liquefied with 1mL Muller Hinton (MH) and serially 
diluted prior to plating in triplicate on blood- free charcoal based selective medium and incubating 
under microaerophilic conditions at 42 deg C.  Colony counting was completed following incubation 
and the number of cfu from test groups was compared with control groups.  
4. Result and Discussion 
The result from this study (Fig.1) indicates a reduction in the colonisation of C. jejuni in chickens 
vaccinated with various Campylobacter antigens. Although the maximum reduction in colonisation 
was 2-3 logs, this is not yet sufficient for commercial vaccine purposes (5 log reduction is desired). 
However, these results indicate the efficiency of STM-1 mutant to deliver Campylobacter related 
antigens in chickens, and when an optimal antigen combination is found may lead to greater reduction 
in colonisation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Analysis of Campylobacter colony forming units after vaccination and subsequent challenge. 
Colonisation is CFU/ g caecal content. 
 
 Other modifications can include the choice of suitable promoters [13] which can facilitate higher 
expression of foreign protein, specifically from the chromosomal location [7], as this will not only 
generate higher immune responses against the delivered antigens but also will assure the stability of the 
foreign construct. Although the location of expression of foreign protein i.e. plasmid or chromosomal 
location, did not have a major effect on reduction in colonisation, the chromosomal location is  
preferable as this not only allows for the stability of the construct and protein expression, but for 
commercial use it will ensure no contamination of other gut flora with plasmid. 
 
However, selection of optimal Campylobacter antigen or antigens is most important as the choice of 
antigenic protein is crucial to develop effective vaccination against the pathogens [4, 14-16]. This is 
one of the most difficult hurdles to overcome as we are still filling the gap in our understanding of 
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Campylobacter pathogenesis and metabolism. Genome mining approaches for candidate proteins are 
currently being undertaken in the search for such candidates.  
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